Animal model studies indicate a candidate biomarker for sorafenib treatment of hepatocellular carcinoma

Elad Horwitz; Ilan Stein; Yinon Ben-Neriah; Eli Pikarsky

doi:https://doi.org/10.4161/23723548.2014.968028

Animal model studies indicate a candidate biomarker for sorafenib treatment of hepatocellular carcinoma

Elad Horwitz, Ilan Stein, Yinon Ben-Neriah, Eli Pikarsky

Department of Immunology and Cancer Research

The Hebrew University of Jerusalem

Research output: Contribution to journal › Article › peer-review

Abstract

In contrast to common genomic amplifications that support cancer cell growth by rewiring intracellular signaling, VEGFA amplification drives tumor cell proliferation via the tumor microenvironment. VEGFA amplification is present in a subset of mouse and human hepatocellular carcinomas (HCCs) that appear to be particularly sensitive to sorafenib treatment, indicating its potential value as a biomarker for HCC treatment.

Original language	English
Article number	e968028
Journal	Molecular and Cellular Oncology
Volume	2
Issue number	1
DOIs	https://doi.org/10.4161/23723548.2014.968028
State	Published - 2 Jan 2015

Keywords

HCC
VEGFA
copy number variation
genomic amplification
macrophages
mouse model
sorafenib

All Science Journal Classification (ASJC) codes

Molecular Medicine
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://doi.org/10.4161/23723548.2014.968028

Cite this

@article{08e7b7c317bc4bfe94ff9f79d539bcdc,

title = "Animal model studies indicate a candidate biomarker for sorafenib treatment of hepatocellular carcinoma",

abstract = "In contrast to common genomic amplifications that support cancer cell growth by rewiring intracellular signaling, VEGFA amplification drives tumor cell proliferation via the tumor microenvironment. VEGFA amplification is present in a subset of mouse and human hepatocellular carcinomas (HCCs) that appear to be particularly sensitive to sorafenib treatment, indicating its potential value as a biomarker for HCC treatment.",

keywords = "HCC, VEGFA, copy number variation, genomic amplification, macrophages, mouse model, sorafenib",

author = "Elad Horwitz and Ilan Stein and Yinon Ben-Neriah and Eli Pikarsky",

note = "Publisher Copyright: {\textcopyright} 2015, Published with license by Taylor & Francis Group, LLC.",

year = "2015",

month = jan,

day = "2",

doi = "https://doi.org/10.4161/23723548.2014.968028",

language = "الإنجليزيّة",

volume = "2",

journal = "Molecular and Cellular Oncology",

issn = "2372-3556",

publisher = "Taylor and Francis Ltd.",

number = "1",

}

TY - JOUR

T1 - Animal model studies indicate a candidate biomarker for sorafenib treatment of hepatocellular carcinoma

AU - Horwitz, Elad

AU - Stein, Ilan

AU - Ben-Neriah, Yinon

AU - Pikarsky, Eli

PY - 2015/1/2

Y1 - 2015/1/2

N2 - In contrast to common genomic amplifications that support cancer cell growth by rewiring intracellular signaling, VEGFA amplification drives tumor cell proliferation via the tumor microenvironment. VEGFA amplification is present in a subset of mouse and human hepatocellular carcinomas (HCCs) that appear to be particularly sensitive to sorafenib treatment, indicating its potential value as a biomarker for HCC treatment.

AB - In contrast to common genomic amplifications that support cancer cell growth by rewiring intracellular signaling, VEGFA amplification drives tumor cell proliferation via the tumor microenvironment. VEGFA amplification is present in a subset of mouse and human hepatocellular carcinomas (HCCs) that appear to be particularly sensitive to sorafenib treatment, indicating its potential value as a biomarker for HCC treatment.

KW - HCC

KW - VEGFA

KW - copy number variation

KW - genomic amplification

KW - macrophages

KW - mouse model

KW - sorafenib

UR - http://www.scopus.com/inward/record.url?scp=85051794937&partnerID=8YFLogxK

U2 - https://doi.org/10.4161/23723548.2014.968028

DO - https://doi.org/10.4161/23723548.2014.968028

M3 - مقالة

SN - 2372-3556

VL - 2

JO - Molecular and Cellular Oncology

JF - Molecular and Cellular Oncology

IS - 1

M1 - e968028

ER -

Animal model studies indicate a candidate biomarker for sorafenib treatment of hepatocellular carcinoma

Abstract

Keywords

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this